Vascular growth factors for coronary angiogenesis

Journal of Interventional Cardiology

Volumn 15, Issue 6, 2002, Pages 511-518

  Lee, Chi Hang ^a   Smits, Pieter C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ATHEROSCLEROSIS; BONE DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; GENE THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEINURIA; RETINOPATHY; REVASCULARIZATION; SIDE EFFECT; TUMOR GROWTH;

EID: 0036892770     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2002.tb01097.x     Document Type: Conference Paper

References (47)

1. Hughes SE, Crossman D, Hall PA. Expression of basic and acidic fibroblast growth factors and their receptor in normal and atherosclerotic human arteries. Cardiovasc Res 1993;27:1214-1219.
2. Li J, Brown LF, Hibberd MG, et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996;270:H1803-1811.
3. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
4. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischemic limb. Lancet 1996;358:370-374.
5. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-439.
6. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
7. Murphara T, Horowitz JR, Silver M, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998;87:99-107.
8. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-11954.
9. Slavin J. Fibroblast growth factors: At the heart of angiogenesis. Cell Biol Int 1995;19:431-444.
10. Battler A, Scheinowitz M, Bor A, et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 1993;22:2001-2006.
11. Yanagisawa-Miwa A, Uchida Y, Nakamura F, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992;257:1401-1403.
12. Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 2000;102:898-901.
13. Edelman ER, Mathiowitz E, Langer R, et al. Controlled and modulated release of basic fibroblast growth factor. Biomaterials 1991;12:619-626.
14. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med 2001;7:33-40.
15. Losordo DW, Pickering JG, Takeshita S, et al. Use of the rabbit ear artery to serially assess foreign protein secretion after site-specific arterial gene transfer in vivo. Evidence that anatomic identification of successful gene transfer may under-estimate the potential magnitude of transgene expression. Circulation 1994;89:785-792.
16. Takeshita S, Losordo DW, Kearney M, et al. Time course of recombinant protein secretion after liposome-mediated gene transfer in a rabbit arterial organ culture model. Lab Invest 1994;71:387-391.
17. Leotta E, Patejunas G, Murphy G, et al. Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure. J Thorac Cardiovasc Surg 2002;123:1101-1113.
18. Hendel RC, Henry TD, Rocha-Singh K, et al. Effect of intra-coronary recombinant human vascular endothelial growth factor on myocardial perfusion: Evidence for a dose-dependent effect. Circulation 2000;101:118-121.
19. Henry T, Annex B, Azrin M, et al. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor- the VIVA trial. (abstract) J Am Coll Cardiol 1999;33:874.
20. Sato K, Wu T, Laham RJ, et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 2001;37:616-623.
21. Sato K, Laham RJ, Pearlman JD, et al. Efficacy of intracoronary versus intravenous FGF-2 in pig model of chronic myocardial ischemia. Ann Thorac Surg 2000;70:2113-2118.
22. Lopez JJ, Laham RJ, Carrozza JP, et al. Hemodynamic effects of intracoronary VEGF delivery: Evidence of tachyphylaxis and NO dependence of response. Am J Physiol 1997;273:H1317-H1323.
23. Magovern CJ, Mack CA, Zhang J, et al. Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector. Ann Thorac Surg 1996;62:425-434.
24. Mack CA, Patel SR, Schwarz EA, et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998;115:168-176.
25. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-474.
26. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-1123.
27. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-2804.
28. Kornowski R, Hong MK, Gepstein L, et al. Preliminary animal and clinical experiences using an electromechanical endocardial mapping procedure to distinguish infarcted from healthy myocardium. Circulation 1998;98:1116-1124.
29. Vale PR, Losordo DW, Tkebuchava T, et al. Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping. J Am Coll Cardiol 1999;34:246-254.
30. Kornowski R, Leon MB, Fuchs S, et al. Electromagnetic guidance for catheter-based transendocardial injection: A platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models. J Am Coll Cardiol 2000;35:1031-1039.
31. Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000;102:965-974.
32. Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001;103:2138-2143.
33. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-2018.
34. Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation 1998;97:645-650.
35. Sellke FW, Laham RJ, Edelman ER, et al. Therapeutic angiogenesis with basic fibroblast growth factor: Technique and early results. Ann Thorac Surg 1998;65:1540-1545.
36. Laham RJ, Selke FW, Edelman ER, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery. Results of phase I randomized, double-blind, placebo-controlled trial. Circulation 1999;100:1865-1871.
37. Ruel M, Laham RJ, Parker JA, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002;124:28-34.
38. Unger EF, Goncalves L, Epstein SE, et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 2000;85:1414-1419.
39. Laham RJ, Chronos NA, Pike M, et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000;36:2132-2139.
40. Udelson JE, Dilsizian V, Laham RJ, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102:1605-1610.
41. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2. Double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-793.
42. Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996;2:534-539.
43. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-1297.
44. Vale P, Losordo D, Dunnington C, et al. Direct myocardial injection of phVEGF165: Results of complete patient cohort in phase 1/2 clinical trial. Circulation 1999;100:I-477
45. Pearlman JD, Hibberd MG, Chuang ML, et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med 1995;1:1085-1089.
46. Miyagawa S, Sawa Y, Taketani S. Myocardial regeneration therapy for heart failure: Hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 2002;105:2556-2561.
47. Morishita R, Sakaki M, Yamamoto K. Impairment of collateral formation in lipoprotein(a) transgenic mice: Therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation 2002;105:1491-1496.